Antoine Briens
Finance Analyst, DEBIOPHARM S.A.
Lausanne - Switzerland
| English | French |
Schools attended |
Lycée Henri Bergson (Classe préparatoire HEC) |
Since 2007: DEBIOPHARM S.A. |
Controlling Manager
| |
Now, I am reponsible for the Controlling service and I manage another financial analyst. I am currently implementing Cognos Planning to run the financial budgets. This is a very interesting experience as "project manager". This will allow the budget process to be more efficient, more secure and we will be able to provide more added-value to decision-makers. I am also a privileged contact concerning financial matters for (Pharmaceutical) Project managers and Business managers : sustain change management, build forecasts, add calculations, etc. About Debiopharm: Debiopharm, based in Lausanne, Switzerland, is a privately owned company founded in 1979, specializing in ethical drug development and registration. The drug development expertise covers the formulation, manufacturing, pre-clinical and clinical stages up to marketing authorization, both in the USA and in Europe. Main products are oncology blockbusters such as Eloxatine and Decapeptyl. | |
Sector: Biotech |
Since 2004: DEBIOPHARM S.A. |
Finance Analyst
| |
My role as a Financial Analyst: First, I settled all the elements of an efficient Controlling system (yearly and revised budgets, monthly & on-line reporting, specific analyses, treasury forecasts) provided by the new accounting software (Pro-Concept ERP). This required to understand the business, clean and organize the data, create SQL requests and reports through the ERP and Excel. In the same time, I had to explain to all users the new concepts, procedures and tools, and keep an attentive listening to manager needs. About Debiopharm: Debiopharm, based in Lausanne, Switzerland, is a privately owned company founded in 1979, specializing in ethical drug development and registration. The drug development expertise covers the formulation, manufacturing, pre-clinical and clinical stages up to marketing authorization, both in the USA and in Europe. Main products are oncology blockbusters such as Eloxatine and Decapeptyl. | |
Sector: Biotech |
